section name header

Pronunciation

e-le-TRIP-tan

Classifications

Therapeutic Classification: vascular headache suppressants

Pharmacologic Classification: five ht1 agonists

Indications

REMS


Action

  • Acts as an agonist at specific 5-hydroxy-tryptamine receptor sites in intracranial blood vessels and sensory trigeminal nerves.
Therapeutic effects:
  • Cranial vessel vasoconstriction with resultant decrease in migraine headache.

Pharmacokinetics

Absorption: 50% absorbed after oral administration.

Distribution: Enters breast milk.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP3A4 enzyme system.

Half-Life: 4 hr.

Time/Action Profile

(decreased migraine pain)

ROUTEONSETPEAKDURATION
POwithin 2 hr2 hrup to 24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ECG changes, angina, chest tightness/pressure, coronary vasospasm, MI, transient hypertension, VENTRICULAR FIBRILLATION, VENTRICULAR TACHYCARDIA

GI: abdominal pain, dry mouth, dysphagia, nausea

Neuro: dizziness, drowsiness, paresthesia, weakness

Misc: ANAPHYLAXIS

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Relpax